{"id": "Dyslipidemia_CKD","name": "Dyslipidemia CKD Workflow","composed": false,"node_type": "composite_task","workflow_state": "activeState","decisional_state": "chosenState","description": "CKD including those treated with Chronic Dialysis or Kidney Transplant","children": [{"id": "prior_lipid_profile","name": "Prior lipid profile?","composed": true,"in_workflow": "Dyslipidemia_CKD","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","description": "1. In adults with newly identified CKD (including those treated with chronic dialysis or kidney transplantation), we recommend evaluation with a lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides). (1C)\n2. In adults with CKD (including those treated with chronic dialysis or kidney transplantation), follow-up measurement of lipid levels is not required for the majority of patients. (Not Graded)","inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_lipid_profile'><\/span><div id='code_lipid_profile' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean'>Prior measurement of lipid profile: <label><input type='radio' name='code_lipid_profile' id='code_lipid_profile-yes' code='code_lipid_profile-yes' value='yes' \/>yes<\/label>&nbsp;&nbsp;<label><input type='radio' name='code_lipid_profile' id='code_lipid_profile-no' code='code_lipid_profile-no' value='no' \/>no<\/label><\/div><\/td><\/tr><\/table>\n","children": [{"id": "Dyslipidemia_Treatment-2","name": "Dyslipidemia Treatment","composed": false,"in_workflow": "Dyslipidemia_CKD","node_type": "composite_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "prior lipid profile","description": "Established CKD with previous measurement of lipid profile."},"children": [{"id": "Followup_Lipid_Profile-2","name": "Followup Lipid Profile","composed": false,"in_workflow": "Dyslipidemia_CKD","node_type": "composite_task","workflow_state": "inactiveState","decisional_state": "chosenState","description": "Follow-up measurement of LDL-C (or entire lipid profile) should be reserved for instances where the results would alter management.","children": [{"id": "assess_suspect_sec_cause-2","name": "Suspect secondary dyslipidemia cause?","composed": true,"in_workflow": "Followup_Lipid_Profile-2","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","description": "Do you suspect the patient has developed a new secondary cause of dyslipidemia?","inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_sec_cause'><\/span><div id='code_sec_cause' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean'>Suspect secondary dyslipidemia cause?: <label><input type='radio' name='code_sec_cause' id='code_sec_cause-yes' code='code_sec_cause-yes' value='yes' \/>yes<\/label>&nbsp;&nbsp;<label><input type='radio' name='code_sec_cause' id='code_sec_cause-no' code='code_sec_cause-no' value='no' \/>no<\/label><\/div><\/td><\/tr><\/table>\n","children": [{"id": "sec_cause_followup-2","name": "Followup lipid profile","composed": false,"in_workflow": "Followup_Lipid_Profile-2","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "yes"},"description": "Follow-up measurement of the lipid profile is suggested."},{"id": "assess_current_treatment-2","name": "Already on statins?","composed": false,"in_workflow": "Followup_Lipid_Profile-2","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "no"},"description": "Is the patient already on a statin?","inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_patient_on_statins'><\/span><div id='code_patient_on_statins' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean'>Already on statins?: <label><input type='radio' name='code_patient_on_statins' id='code_patient_on_statins-yes' code='code_patient_on_statins-yes' value='yes' \/>yes<\/label>&nbsp;&nbsp;<label><input type='radio' name='code_patient_on_statins' id='code_patient_on_statins-no' code='code_patient_on_statins-no' value='no' \/>no<\/label><\/div><\/td><\/tr><\/table>\n","children": [{"id": "yes_statins_no_followup-2","name": "No followup","composed": false,"in_workflow": "Followup_Lipid_Profile-2","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "receiving statins"},"description": "No follow-up measurement of the lipid profile is suggested."},{"id": "reassess_10_year_cv_risk-2","name": "Reassessing 10 year CV risk?","composed": false,"in_workflow": "Followup_Lipid_Profile-2","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "no statins"},"description": "Are you reassessing 10 year CV risk to look for an indication for statin treatment?","inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_10_year_cv_risk'><\/span><div id='code_10_year_cv_risk' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean'>Reassessing 10 year CV risk?: <label><input type='radio' name='code_10_year_cv_risk' id='code_10_year_cv_risk-yes' code='code_10_year_cv_risk-yes' value='yes' \/>yes<\/label>&nbsp;&nbsp;<label><input type='radio' name='code_10_year_cv_risk' id='code_10_year_cv_risk-no' code='code_10_year_cv_risk-no' value='no' \/>no<\/label><\/div><\/td><\/tr><\/table>\n","children": [{"id": "yes_reassess_followup-2","name": "Followup lipid profile","composed": false,"in_workflow": "Followup_Lipid_Profile-2","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "yes"},"description": "Some patients may prefer to know their levels: therefore, the need for follow-up can be assessed on a per-patient basis. \n\tHowever, there is no evidence to followup lipid profile."},{"id": "no_reassess_no_followup-2","name": "No followup","composed": false,"in_workflow": "Followup_Lipid_Profile-2","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "no"},"description": "No follow-up measurement of the lipid profile is suggested."}]}]}]}]},{"id": "Pharmacological_Cholesterol_Lowering_Treatment-2","name": "Pharmacological Cholesterol Lowering Treatment","composed": true,"in_workflow": "Dyslipidemia_Treatment-2","node_type": "composite_task","workflow_state": "inactiveState","decisional_state": "chosenState","children": [{"id": "assess_age_start-2","name": "Age?","composed": true,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-2","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_age'><\/span><div property='http:\/\/hl7.org\/fhir\/Observation.valueQuantity' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.system' resource='http:\/\/unitsofmeasure.org'><\/span><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.code'>year<\/span>Age? <input type='number' id='code_age' code='code_age' min='1' max='120' step='1' size='2' property='http:\/\/hl7.org\/fhir\/Quantity.value' \/> (1-120)<\/div><\/td><\/tr><\/table>\n","children": [{"id": "assess_egfr_value-2","name": "eGFR value?","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-2","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": ">= 50 years"},"inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_egfr'><\/span><div property='http:\/\/hl7.org\/fhir\/Observation.valueQuantity' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.system' resource='http:\/\/unitsofmeasure.org'><\/span><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.code'>ml\/min\/ 1.73m2<\/span>eGFR value? <input type='number' id='code_egfr' code='code_egfr' min='1' max='200' step='1' size='2' property='http:\/\/hl7.org\/fhir\/Quantity.value' \/> (1-200)<\/div><\/td><\/tr><\/table>\n","children": [{"id": "treat_statin_egfr-2","name": "treat with statins","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-2","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": ">=60","description": ">=60 ml\/min\/ 1.73m2"},"description": "2.1.2: In adults aged >=50 years with CKD and eGFR>=60 ml\/min\/1.73m2 (GFR categories G1-G2) we recommend treatment with a statin. (1B)","insert": "<b>Contra-indications for statins:<\/b>\n<ul style=\"margin: 0; padding: 0 0 0 15px;\">\n\t<li>Active liver disease, high alcohol consumption or pregnancy.<\/li>\n    <li>Women with childbearing potential should only use statin if there is reliable contraception.<\/li>\n<\/ul>\n\n<h3>Recommended doses of statins in adults with CKD<\/h3>\n\n<table class=\"statin_dosages\">\n\t<tr>\n\t\t<th>Statin<\/th>\n\t\t<th><div class=\"tooltip2\">eGFR<span>estimated glomerular filtration rate<\/span><\/div> G1 - G2 (<a href=\"img\/Prognosis of CKD by GFR and albuminuria category.png\" target=\"_blank\" style=\"font-weight: normal\">details<\/a>)<\/th>\n\t\t<th>\n\t\t\t<div class=\"tooltip2\">eGFR<span>estimated glomerular filtration rate<\/span><\/div> G3a - G5\n\t\t\t<div class=\"tooltip2\">**<span>incl. dialysis or kidney transplant patients<\/span><\/div>\n\t\t\t(<a href=\"img\/Prognosis of CKD by GFR and albuminuria category.png\" target=\"_blank\" style=\"font-weight: normal\">details<\/a>)\n\t\t<\/th>\n\t<\/tr>\n\t<tr>\n\t\t<td><\/td>\n\t\t<td><span style=\"font-size: 14px;\">(60 to >=90 ml\/min\/1.73m&sup2)<\/span><\/td>\n\t\t<td><span style=\"font-size: 14px;\">(up to 59 ml\/min\/1.73m&sup2)<\/span><\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Lovastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td><div class=\"tooltip2\">nd<span>not done or not studied<\/span><\/div><\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Fluvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>80<div class=\"tooltip2\"><sup>1<\/sup><span>Data based on ALERT.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Atorvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>20<div class=\"tooltip2\"><sup>2<\/sup><span>Data based on 4D.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Rosuvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>10<div class=\"tooltip2\"><sup>3<\/sup><span>Data based on AURORA.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Simvastatin\/Ezetmibe<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>20 \/ 10<div class=\"tooltip2\"><sup>4<\/sup><span>Data based on SHARP.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Pravastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>40 mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Simvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>40 mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Pitavastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>2 mg\/d<\/td>\n\t<\/tr>\n<\/table>\n\n<p class=\"dosage_note\">** incl. dialysis or kidney transplant patients.<\/p>\n<p class=\"dosage_note\">All statins may not be available in all countries. Lower doses than those used in major trials of statins in CKD populations may be appropriate in Asian countries. Note that rosuvastatin 40mg daily is not recommended for use in CKD 1-2 non- transplant patients, as it may increase the risk of adverse renal events. Cyclosporin inhibits the metabolism of certain statins resulting in higher blood levels. Data based on <sup>1<\/sup>ALERT, <sup>2<\/sup>4D, <sup>3<\/sup>AURORA, <sup>4<\/sup>SHARP. Abbreviations: eGFR, estimated glomerular filtration rate; GP, general population; nd, not done or not studied.<\/p>\n"},{"id": "assess_kidney_transplant-2","name": "Kidney transplant?","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-2","otherParents": [{"id": "assess_age_start-2","condition": {"label": "18-49 years"}}],"node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "< 60","description": "< 60 ml\/min\/ 1.73m2"},"inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_kidney_transplant'><\/span><div id='code_kidney_transplant' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean'>Kidney transplant?: <label><input type='radio' name='code_kidney_transplant' id='code_kidney_transplant-yes' code='code_kidney_transplant-yes' value='yes' \/>yes<\/label>&nbsp;&nbsp;<label><input type='radio' name='code_kidney_transplant' id='code_kidney_transplant-no' code='code_kidney_transplant-no' value='no' \/>no<\/label><\/div><\/td><\/tr><\/table>\n","children": [{"id": "treat_statin_kidney_transplant-2","name": "treat with statins","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-2","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "yes"},"description": "2.4: In adult kidney transplant recipients, we suggest treatment with a statin. (2B)","insert": "<b>Contra-indications for statins:<\/b>\n<ul style=\"margin: 0; padding: 0 0 0 15px;\">\n\t<li>Active liver disease, high alcohol consumption or pregnancy.<\/li>\n    <li>Women with childbearing potential should only use statin if there is reliable contraception.<\/li>\n<\/ul>\n\n<h3>Recommended doses of statins in adults with CKD<\/h3>\n\n<table class=\"statin_dosages\">\n\t<tr>\n\t\t<th>Statin<\/th>\n\t\t<th><div class=\"tooltip2\">eGFR<span>estimated glomerular filtration rate<\/span><\/div> G1 - G2 (<a href=\"img\/Prognosis of CKD by GFR and albuminuria category.png\" target=\"_blank\" style=\"font-weight: normal\">details<\/a>)<\/th>\n\t\t<th>\n\t\t\t<div class=\"tooltip2\">eGFR<span>estimated glomerular filtration rate<\/span><\/div> G3a - G5\n\t\t\t<div class=\"tooltip2\">**<span>incl. dialysis or kidney transplant patients<\/span><\/div>\n\t\t\t(<a href=\"img\/Prognosis of CKD by GFR and albuminuria category.png\" target=\"_blank\" style=\"font-weight: normal\">details<\/a>)\n\t\t<\/th>\n\t<\/tr>\n\t<tr>\n\t\t<td><\/td>\n\t\t<td><span style=\"font-size: 14px;\">(60 to >=90 ml\/min\/1.73m&sup2)<\/span><\/td>\n\t\t<td><span style=\"font-size: 14px;\">(up to 59 ml\/min\/1.73m&sup2)<\/span><\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Lovastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td><div class=\"tooltip2\">nd<span>not done or not studied<\/span><\/div><\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Fluvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>80<div class=\"tooltip2\"><sup>1<\/sup><span>Data based on ALERT.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Atorvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>20<div class=\"tooltip2\"><sup>2<\/sup><span>Data based on 4D.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Rosuvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>10<div class=\"tooltip2\"><sup>3<\/sup><span>Data based on AURORA.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Simvastatin\/Ezetmibe<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>20 \/ 10<div class=\"tooltip2\"><sup>4<\/sup><span>Data based on SHARP.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Pravastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>40 mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Simvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>40 mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Pitavastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>2 mg\/d<\/td>\n\t<\/tr>\n<\/table>\n\n<p class=\"dosage_note\">** incl. dialysis or kidney transplant patients.<\/p>\n<p class=\"dosage_note\">All statins may not be available in all countries. Lower doses than those used in major trials of statins in CKD populations may be appropriate in Asian countries. Note that rosuvastatin 40mg daily is not recommended for use in CKD 1-2 non- transplant patients, as it may increase the risk of adverse renal events. Cyclosporin inhibits the metabolism of certain statins resulting in higher blood levels. Data based on <sup>1<\/sup>ALERT, <sup>2<\/sup>4D, <sup>3<\/sup>AURORA, <sup>4<\/sup>SHARP. Abbreviations: eGFR, estimated glomerular filtration rate; GP, general population; nd, not done or not studied.<\/p>\n"},{"id": "assess_dialysis_treatment-2","name": "Treatment with dialysis?","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-2","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "no"},"inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_dialysis_treatment'><\/span><div id='code_dialysis_treatment' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean'>Treatment with dialysis?: <label><input type='radio' name='code_dialysis_treatment' id='code_dialysis_treatment-yes' code='code_dialysis_treatment-yes' value='yes' \/>yes<\/label>&nbsp;&nbsp;<label><input type='radio' name='code_dialysis_treatment' id='code_dialysis_treatment-no' code='code_dialysis_treatment-no' value='no' \/>no<\/label><\/div><\/td><\/tr><\/table>\n","children": [{"id": "assess_statin_use-2","name": "Using statins or statin/ezetimibe?","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-2","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "yes"},"inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_statin_ezetimibe'><\/span><div id='code_statin_ezetimibe' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean'>Using statins or statin\/ezetimibe?: <label><input type='radio' name='code_statin_ezetimibe' id='code_statin_ezetimibe-yes' code='code_statin_ezetimibe-yes' value='yes' \/>yes<\/label>&nbsp;&nbsp;<label><input type='radio' name='code_statin_ezetimibe' id='code_statin_ezetimibe-no' code='code_statin_ezetimibe-no' value='no' \/>no<\/label><\/div><\/td><\/tr><\/table>\n","children": [{"id": "continue_statin_treatment-2","name": "continue statin or statin/ezetimibe","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-2","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "yes"},"description": "2.3.2: In patients already receiving statins or statin\/ezetimibe combination at the time of dialysis initiation, we suggest that these agents be continued. (2C)","insert": "<b>Contra-indications for statins:<\/b>\n<ul style=\"margin: 0; padding: 0 0 0 15px;\">\n\t<li>Active liver disease, high alcohol consumption or pregnancy.<\/li>\n    <li>Women with childbearing potential should only use statin if there is reliable contraception.<\/li>\n<\/ul>\n\n<h3>Recommended doses of statins in adults with CKD<\/h3>\n\n<table class=\"statin_dosages\">\n\t<tr>\n\t\t<th>Statin<\/th>\n\t\t<th><div class=\"tooltip2\">eGFR<span>estimated glomerular filtration rate<\/span><\/div> G1 - G2 (<a href=\"img\/Prognosis of CKD by GFR and albuminuria category.png\" target=\"_blank\" style=\"font-weight: normal\">details<\/a>)<\/th>\n\t\t<th>\n\t\t\t<div class=\"tooltip2\">eGFR<span>estimated glomerular filtration rate<\/span><\/div> G3a - G5\n\t\t\t<div class=\"tooltip2\">**<span>incl. dialysis or kidney transplant patients<\/span><\/div>\n\t\t\t(<a href=\"img\/Prognosis of CKD by GFR and albuminuria category.png\" target=\"_blank\" style=\"font-weight: normal\">details<\/a>)\n\t\t<\/th>\n\t<\/tr>\n\t<tr>\n\t\t<td><\/td>\n\t\t<td><span style=\"font-size: 14px;\">(60 to >=90 ml\/min\/1.73m&sup2)<\/span><\/td>\n\t\t<td><span style=\"font-size: 14px;\">(up to 59 ml\/min\/1.73m&sup2)<\/span><\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Lovastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td><div class=\"tooltip2\">nd<span>not done or not studied<\/span><\/div><\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Fluvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>80<div class=\"tooltip2\"><sup>1<\/sup><span>Data based on ALERT.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Atorvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>20<div class=\"tooltip2\"><sup>2<\/sup><span>Data based on 4D.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Rosuvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>10<div class=\"tooltip2\"><sup>3<\/sup><span>Data based on AURORA.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Simvastatin\/Ezetmibe<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>20 \/ 10<div class=\"tooltip2\"><sup>4<\/sup><span>Data based on SHARP.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Pravastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>40 mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Simvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>40 mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Pitavastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>2 mg\/d<\/td>\n\t<\/tr>\n<\/table>\n\n<p class=\"dosage_note\">** incl. dialysis or kidney transplant patients.<\/p>\n<p class=\"dosage_note\">All statins may not be available in all countries. Lower doses than those used in major trials of statins in CKD populations may be appropriate in Asian countries. Note that rosuvastatin 40mg daily is not recommended for use in CKD 1-2 non- transplant patients, as it may increase the risk of adverse renal events. Cyclosporin inhibits the metabolism of certain statins resulting in higher blood levels. Data based on <sup>1<\/sup>ALERT, <sup>2<\/sup>4D, <sup>3<\/sup>AURORA, <sup>4<\/sup>SHARP. Abbreviations: eGFR, estimated glomerular filtration rate; GP, general population; nd, not done or not studied.<\/p>\n"},{"id": "do_not_initiate_statins-2","name": "do not initiate statins","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-2","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "no"},"description": "2.3.1: In adults with dialysis-dependent CKD, we suggest that statins or statin\/ezetimibe combination not be initiated. (2A)"}]},{"id": "assess_age_no_dialysis-2","name": "Age?","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-2","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "no"},"inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_age'><\/span><div property='http:\/\/hl7.org\/fhir\/Observation.valueQuantity' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.system' resource='http:\/\/unitsofmeasure.org'><\/span><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.code'>year<\/span>Age? <input type='number' id='code_age' code='code_age' min='1' max='120' step='1' size='2' property='http:\/\/hl7.org\/fhir\/Quantity.value' \/> (1-120)<\/div><\/td><\/tr><\/table>\n","children": [{"id": "assess_cv_risk-2","name": "assess CV risk","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-2","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "18-49 years"},"description": "Note that CV risk should be re-assessed on an annual basis, as changes in clinical condition may warrant treatment with a statin.","inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_no_cv_risk_factors'><\/span><label><input type='checkbox' id='code_no_cv_risk_factors' code='code_no_cv_risk_factors' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_prior_mi,code_prior_coronary_revascularization,code_prior_ischemic_stroke,code_prior_transient_ischemic_attack,code_diabetes,code_estimated_10-year_incidence_coronary_death,code_likelihood_non_fatal_mi' mandatory='false' \/>No CV risk factors<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_prior_mi'><\/span><label><input type='checkbox' id='code_prior_mi' code='code_prior_mi' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_cv_risk_factors' mandatory='false' \/>Prior MI?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_prior_coronary_revascularization'><\/span><label><input type='checkbox' id='code_prior_coronary_revascularization' code='code_prior_coronary_revascularization' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_cv_risk_factors' mandatory='false' \/>Prior Coronary Revascularization?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_prior_ischemic_stroke'><\/span><label><input type='checkbox' id='code_prior_ischemic_stroke' code='code_prior_ischemic_stroke' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_cv_risk_factors' mandatory='false' \/>Prior ischemic stroke?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_prior_transient_ischemic_attack'><\/span><label><input type='checkbox' id='code_prior_transient_ischemic_attack' code='code_prior_transient_ischemic_attack' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_cv_risk_factors' mandatory='false' \/>Prior transient ischemic attack?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_diabetes'><\/span><label><input type='checkbox' id='code_diabetes' code='code_diabetes' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_cv_risk_factors' mandatory='false' \/>Diabetes?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_estimated_10-year_incidence_coronary_death'><\/span><label><input type='checkbox' id='code_estimated_10-year_incidence_coronary_death' code='code_estimated_10-year_incidence_coronary_death' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_cv_risk_factors' mandatory='false' \/>Estimated 10-year incidence of coronary death?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_likelihood_non_fatal_mi'><\/span><div property='http:\/\/hl7.org\/fhir\/Observation.valueQuantity' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.system' resource='http:\/\/unitsofmeasure.org'><\/span><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.code'>%<\/span>Likelihood of non-fatal MI (<a href=\"https:\/\/www.mdcalc.com\/framingham-risk-score-hard-coronary-heart-disease\" target=\"_blank\">calculate<\/a>) <input type='number' id='code_likelihood_non_fatal_mi' code='code_likelihood_non_fatal_mi' min='1' max='100' step='1' size='2' property='http:\/\/hl7.org\/fhir\/Quantity.value' \/> (1-100)<\/div><\/td><\/tr><\/table>\n","children": [{"id": "treat_statin_high_risk-2","name": "treat with statin","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-2","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "high risk","description": "Prior MI or\nPrior Coronary revascularization or\nPrior ischemic stroke or Transient ischemic attack or\nDiabetes or\nEstimated 10-year incidence of coronary death or non-fatal MI >10% using a validated risk calculator"},"description": "2.2: In adults aged 18\u201349 years with CKD but not treated with chronic dialysis or kidney transplantation, we\nsuggest statin treatment in people with one or more of the following (2A):\n\u2022\tknown coronary disease (myocardial infarction or coronary revascularization)\n\u2022\tdiabetes mellitus\n\u2022\tprior ischemic stroke\n\u2022\testimated 10-year incidence of coronary death or non-fatal myocardial infarction >10%","insert": "<b>Contra-indications for statins:<\/b>\n<ul style=\"margin: 0; padding: 0 0 0 15px;\">\n\t<li>Active liver disease, high alcohol consumption or pregnancy.<\/li>\n    <li>Women with childbearing potential should only use statin if there is reliable contraception.<\/li>\n<\/ul>\n\n<h3>Recommended doses of statins in adults with CKD<\/h3>\n\n<table class=\"statin_dosages\">\n\t<tr>\n\t\t<th>Statin<\/th>\n\t\t<th><div class=\"tooltip2\">eGFR<span>estimated glomerular filtration rate<\/span><\/div> G1 - G2 (<a href=\"img\/Prognosis of CKD by GFR and albuminuria category.png\" target=\"_blank\" style=\"font-weight: normal\">details<\/a>)<\/th>\n\t\t<th>\n\t\t\t<div class=\"tooltip2\">eGFR<span>estimated glomerular filtration rate<\/span><\/div> G3a - G5\n\t\t\t<div class=\"tooltip2\">**<span>incl. dialysis or kidney transplant patients<\/span><\/div>\n\t\t\t(<a href=\"img\/Prognosis of CKD by GFR and albuminuria category.png\" target=\"_blank\" style=\"font-weight: normal\">details<\/a>)\n\t\t<\/th>\n\t<\/tr>\n\t<tr>\n\t\t<td><\/td>\n\t\t<td><span style=\"font-size: 14px;\">(60 to >=90 ml\/min\/1.73m&sup2)<\/span><\/td>\n\t\t<td><span style=\"font-size: 14px;\">(up to 59 ml\/min\/1.73m&sup2)<\/span><\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Lovastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td><div class=\"tooltip2\">nd<span>not done or not studied<\/span><\/div><\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Fluvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>80<div class=\"tooltip2\"><sup>1<\/sup><span>Data based on ALERT.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Atorvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>20<div class=\"tooltip2\"><sup>2<\/sup><span>Data based on 4D.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Rosuvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>10<div class=\"tooltip2\"><sup>3<\/sup><span>Data based on AURORA.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Simvastatin\/Ezetmibe<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>20 \/ 10<div class=\"tooltip2\"><sup>4<\/sup><span>Data based on SHARP.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Pravastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>40 mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Simvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>40 mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Pitavastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>2 mg\/d<\/td>\n\t<\/tr>\n<\/table>\n\n<p class=\"dosage_note\">** incl. dialysis or kidney transplant patients.<\/p>\n<p class=\"dosage_note\">All statins may not be available in all countries. Lower doses than those used in major trials of statins in CKD populations may be appropriate in Asian countries. Note that rosuvastatin 40mg daily is not recommended for use in CKD 1-2 non- transplant patients, as it may increase the risk of adverse renal events. Cyclosporin inhibits the metabolism of certain statins resulting in higher blood levels. Data based on <sup>1<\/sup>ALERT, <sup>2<\/sup>4D, <sup>3<\/sup>AURORA, <sup>4<\/sup>SHARP. Abbreviations: eGFR, estimated glomerular filtration rate; GP, general population; nd, not done or not studied.<\/p>\n"},{"id": "no_statin_treatment_low_risk-2","name": "do not initiate statins","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-2","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "no","description": "No CV risk factor or \nEstimated 10-year incidence of coronary death or non-fatal MI >10% using a validated risk calculator"}}]},{"id": "treat_statin_no_dialysis-2","name": "treat with statins or statin/ezetimibe","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-2","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": ">= 50 years"},"insert": "<b>Contra-indications for statins:<\/b>\n<ul style=\"margin: 0; padding: 0 0 0 15px;\">\n\t<li>Active liver disease, high alcohol consumption or pregnancy.<\/li>\n    <li>Women with childbearing potential should only use statin if there is reliable contraception.<\/li>\n<\/ul>\n\n<h3>Recommended doses of statins in adults with CKD<\/h3>\n\n<table class=\"statin_dosages\">\n\t<tr>\n\t\t<th>Statin<\/th>\n\t\t<th><div class=\"tooltip2\">eGFR<span>estimated glomerular filtration rate<\/span><\/div> G1 - G2 (<a href=\"img\/Prognosis of CKD by GFR and albuminuria category.png\" target=\"_blank\" style=\"font-weight: normal\">details<\/a>)<\/th>\n\t\t<th>\n\t\t\t<div class=\"tooltip2\">eGFR<span>estimated glomerular filtration rate<\/span><\/div> G3a - G5\n\t\t\t<div class=\"tooltip2\">**<span>incl. dialysis or kidney transplant patients<\/span><\/div>\n\t\t\t(<a href=\"img\/Prognosis of CKD by GFR and albuminuria category.png\" target=\"_blank\" style=\"font-weight: normal\">details<\/a>)\n\t\t<\/th>\n\t<\/tr>\n\t<tr>\n\t\t<td><\/td>\n\t\t<td><span style=\"font-size: 14px;\">(60 to >=90 ml\/min\/1.73m&sup2)<\/span><\/td>\n\t\t<td><span style=\"font-size: 14px;\">(up to 59 ml\/min\/1.73m&sup2)<\/span><\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Lovastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td><div class=\"tooltip2\">nd<span>not done or not studied<\/span><\/div><\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Fluvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>80<div class=\"tooltip2\"><sup>1<\/sup><span>Data based on ALERT.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Atorvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>20<div class=\"tooltip2\"><sup>2<\/sup><span>Data based on 4D.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Rosuvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>10<div class=\"tooltip2\"><sup>3<\/sup><span>Data based on AURORA.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Simvastatin\/Ezetmibe<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>20 \/ 10<div class=\"tooltip2\"><sup>4<\/sup><span>Data based on SHARP.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Pravastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>40 mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Simvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>40 mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Pitavastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>2 mg\/d<\/td>\n\t<\/tr>\n<\/table>\n\n<p class=\"dosage_note\">** incl. dialysis or kidney transplant patients.<\/p>\n<p class=\"dosage_note\">All statins may not be available in all countries. Lower doses than those used in major trials of statins in CKD populations may be appropriate in Asian countries. Note that rosuvastatin 40mg daily is not recommended for use in CKD 1-2 non- transplant patients, as it may increase the risk of adverse renal events. Cyclosporin inhibits the metabolism of certain statins resulting in higher blood levels. Data based on <sup>1<\/sup>ALERT, <sup>2<\/sup>4D, <sup>3<\/sup>AURORA, <sup>4<\/sup>SHARP. Abbreviations: eGFR, estimated glomerular filtration rate; GP, general population; nd, not done or not studied.<\/p>\n"}]}]}]}]},{"hidden": true}]},{"id": "statin_prescribed-2","name": "Statins prescribed?","composed": false,"in_workflow": "Dyslipidemia_Treatment-2","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","description": "Were any statins prescribed for cholesterol lowering treatment?","inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_statin_prescribed'><\/span><div id='code_statin_prescribed' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean'>Any statins prescribed for cholesterol lowering treatment?: <label><input type='radio' name='code_statin_prescribed' id='code_statin_prescribed-yes' code='code_statin_prescribed-yes' value='yes' \/>yes<\/label>&nbsp;&nbsp;<label><input type='radio' name='code_statin_prescribed' id='code_statin_prescribed-no' code='code_statin_prescribed-no' value='no' \/>no<\/label><\/div><\/td><\/tr><\/table>\n","children": [{"id": "no_statin_no_followup-2","name": "No followup","composed": false,"in_workflow": "Dyslipidemia_Treatment-2","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "no"}},{"id": "fasting_serum_tgs_values-2","name": "Check Fasting Serum TGs Values","composed": false,"in_workflow": "Dyslipidemia_Treatment-2","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "yes"},"inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_fasting_serum_tg'><\/span><div property='http:\/\/hl7.org\/fhir\/Observation.valueQuantity' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.system' resource='http:\/\/unitsofmeasure.org'><\/span><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.code'>mmol\/L<\/span>Fasting serum TGs value <input type='number' id='code_fasting_serum_tg' code='code_fasting_serum_tg' min='1' max='100' step='0.01' size='2' property='http:\/\/hl7.org\/fhir\/Quantity.value' \/> (1-100)<\/div><\/td><\/tr><\/table>\n","children": [{"id": "low_fasting_serum_no_followup-2","name": "No followup","composed": false,"in_workflow": "Dyslipidemia_Treatment-2","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "<=5.65mmol/l","description": "<=5.65mmol\/l (>500mg\/dl)"}},{"id": "assess_malnutrition-2","name": "Malnutrition?","composed": false,"in_workflow": "Dyslipidemia_Treatment-2","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": ">5.65mmol/l","description": ">5.65mmol\/l (>500mg\/dl)"},"inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_malnutrition'><\/span><div id='code_malnutrition' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean'>Malnutrition?: <label><input type='radio' name='code_malnutrition' id='code_malnutrition-yes' code='code_malnutrition-yes' value='yes' \/>yes<\/label>&nbsp;&nbsp;<label><input type='radio' name='code_malnutrition' id='code_malnutrition-no' code='code_malnutrition-no' value='no' \/>no<\/label><\/div><\/td><\/tr><\/table>\n","children": [{"id": "prescribe_lifestyle_changes_judiciously-2","name": "Judicious lifestyle changes","composed": false,"in_workflow": "Dyslipidemia_Treatment-2","node_type": "atomic_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "yes","description": "Malnutrition found."},"description": "Prescribe Therapeutic Lifestyle Changes judiciously with caution.","children": [{"hidden": true},{"id": "fasting_serum_tgs_values2-2","name": "Check Fasting Serum TGs Values (2)","composed": false,"in_workflow": "Dyslipidemia_Treatment-2","otherParents": [{"id": "prescribe_lifestyle_changes-2","condition": null}],"node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_fasting_serum_tg'><\/span><div property='http:\/\/hl7.org\/fhir\/Observation.valueQuantity' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.system' resource='http:\/\/unitsofmeasure.org'><\/span><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.code'>mmol\/L<\/span>Fasting serum TGs value <input type='number' id='code_fasting_serum_tg' code='code_fasting_serum_tg' min='1' max='100' step='0.01' size='2' property='http:\/\/hl7.org\/fhir\/Quantity.value' \/> (1-100)<\/div><\/td><\/tr><\/table>\n","children": [{"id": "low_fasting_serum_no_followup2-2","name": "No followup","composed": false,"in_workflow": "Dyslipidemia_Treatment-2","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "<=11.3mmol/l","description": "<=11.3mmol\/l (<=1000mg\/dl)"}},{"id": "avoid_nicotinic_acid-2","name": "Avoid nicotinic acid","composed": false,"in_workflow": "Dyslipidemia_Treatment-2","node_type": "atomic_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": ">11.3mmol/l","description": ">11.3mmol\/l (<=1000mg\/dl)"},"description": "Nicotinic Acid has not been well studied in advanced CKD and therefore is not recommended for the treatment of severe hypertriglyceridemia.","children": [{"id": "assess_prevent_pancreatitis-2","name": "Prevent pancreatitis?","composed": false,"in_workflow": "Dyslipidemia_Treatment-2","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","description": "Have a conversation with patient regarding pros and cons of treatment with statin vs. fibric acid derivatives and their preference, especially regarding prevention of pancreatitis. (Concomitant therapy with fibric acid derivative and a statin is not recommended in patient with CKD due to the potential for toxicity.)","inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_prevent_pancreatitis'><\/span><div id='code_prevent_pancreatitis' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean'>Does the patient place high value on preventing pancreatitis?: <label><input type='radio' name='code_prevent_pancreatitis' id='code_prevent_pancreatitis-yes' code='code_prevent_pancreatitis-yes' value='yes' \/>yes<\/label>&nbsp;&nbsp;<label><input type='radio' name='code_prevent_pancreatitis' id='code_prevent_pancreatitis-no' code='code_prevent_pancreatitis-no' value='no' \/>no<\/label><\/div><\/td><\/tr><\/table>\n","children": [{"id": "prescribe_fibric_acid_pancreatitis-2","name": "Prescribe fibric acid","composed": false,"in_workflow": "Dyslipidemia_Treatment-2","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "yes","description": "Patient places high value on preventing pancreatitis."},"description": "Fibric acid derivatives could be considered. \n\tIf considered, fibric acid should be dose adjusted for kidney function. \n\tFibric acid derivatives might be warranted in patients who place a relatively high value in preventing pancreatitis and a relatively low value on the risk of CV disease."},{"id": "do_not_prescribe_fibric_acid_pancreatitis-2","name": "No fibric acid","composed": false,"in_workflow": "Dyslipidemia_Treatment-2","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "no","description": "Patient does not place high value on preventing pancreatitis."},"description": "Fibric acid derivatives should not be considered."}]}]}]}]},{"id": "prescribe_lifestyle_changes-2","name": "Lifestyle changes","composed": false,"in_workflow": "Dyslipidemia_Treatment-2","node_type": "atomic_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "no","description": "No malnutrition found."},"description": "Prescribe Therapeutic Lifestyle Changes:\n\u2022\tLow Fat diet (<15% total calories)\n\u2022\tReduce monosaccharides & disaccharides intake\n\u2022\tReduce total amount of dietary carbohydrates\n\u2022\tUse fish oils to replace some long-chain TGs","children": []}]}]}]}]}]},{"id": "Evaluate_Lipid_Profile","name": "Evaluate Lipid Profile","composed": false,"in_workflow": "Dyslipidemia_CKD","node_type": "composite_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "no profile","description": "Newly identified CKD or established CKD with no prior measurement of lipid profile."},"children": [{"id": "measure_lipid_profile","name": "Measure lipid profile","composed": true,"in_workflow": "Evaluate_Lipid_Profile","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","description": "1.\tTotal cholesterol\n2.\tLDL cholesterol \n3.\tHDL cholesterol \n4.\tTriglycerides","inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_abnormal_lipid_profile'><\/span><div id='code_abnormal_lipid_profile' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean'>Abnormal lipid profile?: <label><input type='radio' name='code_abnormal_lipid_profile' id='code_abnormal_lipid_profile-yes' code='code_abnormal_lipid_profile-yes' value='yes' \/>yes<\/label>&nbsp;&nbsp;<label><input type='radio' name='code_abnormal_lipid_profile' id='code_abnormal_lipid_profile-no' code='code_abnormal_lipid_profile-no' value='no' \/>no<\/label><\/div><\/td><\/tr><\/table>\n","children": [{"id": "no_dyslipidemia","name": "No action","composed": false,"in_workflow": "Evaluate_Lipid_Profile","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "normal","description": "No abnormal lipid profile."},"description": "No further measurement of lipid profile."},{"id": "rule_out_secondary_causes","name": "Rule out secondary causes","composed": false,"in_workflow": "Evaluate_Lipid_Profile","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "abnormal","description": "Abnormal lipid profile."},"description": "Investigate and treat remediable secondary causes of dyslipidemia.","inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_no_secondary_causes'><\/span><label><input type='checkbox' id='code_no_secondary_causes' code='code_no_secondary_causes' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_nephrotic_syndrome,code_hypothyroidism,code_diabetes,code_excessive_alcohol_consumption,code_liver_disease,code_13-cis-retinioc_acid,code_anti_convulsant,code_highly_active_anti-retroviral_therapy,code_androgens,code_oral_contraceptives,code_corticosteroids,code_cyclosporine,code_sirolimus' mandatory='false' \/>No secondary causes<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_nephrotic_syndrome'><\/span><label><input type='checkbox' id='code_nephrotic_syndrome' code='code_nephrotic_syndrome' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_secondary_causes' mandatory='false' \/>Nephrotic syndrome?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_hypothyroidism'><\/span><label><input type='checkbox' id='code_hypothyroidism' code='code_hypothyroidism' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_secondary_causes' mandatory='false' \/>Hypothyroidism?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_diabetes'><\/span><label><input type='checkbox' id='code_diabetes' code='code_diabetes' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_secondary_causes' mandatory='false' \/>Diabetes?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_excessive_alcohol_consumption'><\/span><label><input type='checkbox' id='code_excessive_alcohol_consumption' code='code_excessive_alcohol_consumption' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_secondary_causes' mandatory='false' \/>Excessive alcohol consumption?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_liver_disease'><\/span><label><input type='checkbox' id='code_liver_disease' code='code_liver_disease' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_secondary_causes' mandatory='false' \/>Liver disease?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_13-cis-retinioc_acid'><\/span><label><input type='checkbox' id='code_13-cis-retinioc_acid' code='code_13-cis-retinioc_acid' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_secondary_causes' mandatory='false' \/>13-cis-retinioc acid?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_anti_convulsant'><\/span><label><input type='checkbox' id='code_anti_convulsant' code='code_anti_convulsant' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_secondary_causes' mandatory='false' \/>Anti-convulsant?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_highly_active_anti-retroviral_therapy'><\/span><label><input type='checkbox' id='code_highly_active_anti-retroviral_therapy' code='code_highly_active_anti-retroviral_therapy' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_secondary_causes' mandatory='false' \/>Highly active anti-retroviral therapy?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_androgens'><\/span><label><input type='checkbox' id='code_androgens' code='code_androgens' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_secondary_causes' mandatory='false' \/>Androgens?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_oral_contraceptives'><\/span><label><input type='checkbox' id='code_oral_contraceptives' code='code_oral_contraceptives' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_secondary_causes' mandatory='false' \/>Oral contraceptives?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_corticosteroids'><\/span><label><input type='checkbox' id='code_corticosteroids' code='code_corticosteroids' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_secondary_causes' mandatory='false' \/>Corticosteroids?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_sirolimus'><\/span><label><input type='checkbox' id='code_sirolimus' code='code_sirolimus' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_secondary_causes' mandatory='false' \/>Sirolimus?<\/label><\/td><\/tr><\/table>\n","children": [{"id": "secondary_causes_found","name": "Treatment or referral","composed": false,"in_workflow": "Evaluate_Lipid_Profile","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "secondary causes","description": "Some secondary causes found."},"description": "Remediable (secondary) causes of dyslipidemia found. Treat secondary causes or refer to specialist."},{"id": "no_secondary_causes_found","name": "No secondary causes","composed": false,"in_workflow": "Evaluate_Lipid_Profile","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "no","description": "No secondary causes found."},"description": "No remediable (secondary) causes of dyslipidemia found."}]}]},{"id": "Dyslipidemia_Treatment-1","name": "Dyslipidemia Treatment","composed": false,"in_workflow": "Dyslipidemia_CKD","node_type": "composite_task","workflow_state": "inactiveState","decisional_state": "chosenState","children": [{"id": "evaluate_severity_dyslipidemia","name": "Evaluate severity dyslipidemia","composed": false,"in_workflow": "Dyslipidemia_CKD","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","description": "Assess fasting triglycerides and LDL-C","inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_fasting_triglycerides'><\/span><div property='http:\/\/hl7.org\/fhir\/Observation.valueQuantity' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.system' resource='http:\/\/unitsofmeasure.org'><\/span><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.code'>mmol\/L<\/span>Fasting triglycerides <input type='number' id='code_fasting_triglycerides' code='code_fasting_triglycerides' min='1' max='100' step='0.01' size='2' property='http:\/\/hl7.org\/fhir\/Quantity.value' \/> (1-100)<\/div><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_ldl_cholesterol'><\/span><div property='http:\/\/hl7.org\/fhir\/Observation.valueQuantity' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.system' resource='http:\/\/unitsofmeasure.org'><\/span><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.code'>mmol\/L<\/span>LDL cholesterol <input type='number' id='code_ldl_cholesterol' code='code_ldl_cholesterol' min='1' max='100' step='0.01' size='2' property='http:\/\/hl7.org\/fhir\/Quantity.value' \/> (1-100)<\/div><\/td><\/tr><\/table>\n","children": [{"id": "severe_dyslipidemia","name": "Referral","composed": false,"in_workflow": "Dyslipidemia_CKD","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "severe","description": "1.Fasting Triglycerides > 11.3mmol\/l (1000 mg\/dl); or\n2. LDL-C > 4.9 mmol\/l(190 mg\/dl)"},"description": "Consider referral to a specialist for further evaluation."},{"id": "Followup_Lipid_Profile-1","name": "Followup Lipid Profile","composed": false,"in_workflow": "Dyslipidemia_CKD","node_type": "composite_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "not severe","description": "1.Fasting Triglycerides <= 11.3mmol\/l (1000 mg\/dl); and\n2. LDL-C <= 4.9 mmol\/l(190 mg\/dl)"},"description": "Follow-up measurement of LDL-C (or entire lipid profile) should be reserved for instances where the results would alter management.","children": [{"id": "assess_suspect_sec_cause-1","name": "Suspect secondary dyslipidemia cause?","composed": true,"in_workflow": "Followup_Lipid_Profile-1","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","description": "Do you suspect the patient has developed a new secondary cause of dyslipidemia?","inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_sec_cause'><\/span><div id='code_sec_cause' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean'>Suspect secondary dyslipidemia cause?: <label><input type='radio' name='code_sec_cause' id='code_sec_cause-yes' code='code_sec_cause-yes' value='yes' \/>yes<\/label>&nbsp;&nbsp;<label><input type='radio' name='code_sec_cause' id='code_sec_cause-no' code='code_sec_cause-no' value='no' \/>no<\/label><\/div><\/td><\/tr><\/table>\n","children": [{"id": "sec_cause_followup-1","name": "Followup lipid profile","composed": false,"in_workflow": "Followup_Lipid_Profile-1","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "yes"},"description": "Follow-up measurement of the lipid profile is suggested."},{"id": "assess_current_treatment-1","name": "Already on statins?","composed": false,"in_workflow": "Followup_Lipid_Profile-1","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "no"},"description": "Is the patient already on a statin?","inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_patient_on_statins'><\/span><div id='code_patient_on_statins' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean'>Already on statins?: <label><input type='radio' name='code_patient_on_statins' id='code_patient_on_statins-yes' code='code_patient_on_statins-yes' value='yes' \/>yes<\/label>&nbsp;&nbsp;<label><input type='radio' name='code_patient_on_statins' id='code_patient_on_statins-no' code='code_patient_on_statins-no' value='no' \/>no<\/label><\/div><\/td><\/tr><\/table>\n","children": [{"id": "yes_statins_no_followup-1","name": "No followup","composed": false,"in_workflow": "Followup_Lipid_Profile-1","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "receiving statins"},"description": "No follow-up measurement of the lipid profile is suggested."},{"id": "reassess_10_year_cv_risk-1","name": "Reassessing 10 year CV risk?","composed": false,"in_workflow": "Followup_Lipid_Profile-1","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "no statins"},"description": "Are you reassessing 10 year CV risk to look for an indication for statin treatment?","inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_10_year_cv_risk'><\/span><div id='code_10_year_cv_risk' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean'>Reassessing 10 year CV risk?: <label><input type='radio' name='code_10_year_cv_risk' id='code_10_year_cv_risk-yes' code='code_10_year_cv_risk-yes' value='yes' \/>yes<\/label>&nbsp;&nbsp;<label><input type='radio' name='code_10_year_cv_risk' id='code_10_year_cv_risk-no' code='code_10_year_cv_risk-no' value='no' \/>no<\/label><\/div><\/td><\/tr><\/table>\n","children": [{"id": "yes_reassess_followup-1","name": "Followup lipid profile","composed": false,"in_workflow": "Followup_Lipid_Profile-1","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "yes"},"description": "Some patients may prefer to know their levels: therefore, the need for follow-up can be assessed on a per-patient basis. \n\tHowever, there is no evidence to followup lipid profile."},{"id": "no_reassess_no_followup-1","name": "No followup","composed": false,"in_workflow": "Followup_Lipid_Profile-1","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "no"},"description": "No follow-up measurement of the lipid profile is suggested."}]}]}]}]}]},{"id": "Pharmacological_Cholesterol_Lowering_Treatment-1","name": "Pharmacological Cholesterol Lowering Treatment","composed": true,"in_workflow": "Dyslipidemia_Treatment-1","node_type": "composite_task","workflow_state": "inactiveState","decisional_state": "chosenState","children": [{"id": "assess_age_start-1","name": "Age?","composed": true,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-1","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_age'><\/span><div property='http:\/\/hl7.org\/fhir\/Observation.valueQuantity' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.system' resource='http:\/\/unitsofmeasure.org'><\/span><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.code'>year<\/span>Age? <input type='number' id='code_age' code='code_age' min='1' max='120' step='1' size='2' property='http:\/\/hl7.org\/fhir\/Quantity.value' \/> (1-120)<\/div><\/td><\/tr><\/table>\n","children": [{"id": "assess_egfr_value-1","name": "eGFR value?","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-1","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": ">= 50 years"},"inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_egfr'><\/span><div property='http:\/\/hl7.org\/fhir\/Observation.valueQuantity' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.system' resource='http:\/\/unitsofmeasure.org'><\/span><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.code'>ml\/min\/ 1.73m2<\/span>eGFR value? <input type='number' id='code_egfr' code='code_egfr' min='1' max='200' step='1' size='2' property='http:\/\/hl7.org\/fhir\/Quantity.value' \/> (1-200)<\/div><\/td><\/tr><\/table>\n","children": [{"id": "treat_statin_egfr-1","name": "treat with statins","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-1","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": ">=60","description": ">=60 ml\/min\/ 1.73m2"},"description": "2.1.2: In adults aged >=50 years with CKD and eGFR>=60 ml\/min\/1.73m2 (GFR categories G1-G2) we recommend treatment with a statin. (1B)","insert": "<b>Contra-indications for statins:<\/b>\n<ul style=\"margin: 0; padding: 0 0 0 15px;\">\n\t<li>Active liver disease, high alcohol consumption or pregnancy.<\/li>\n    <li>Women with childbearing potential should only use statin if there is reliable contraception.<\/li>\n<\/ul>\n\n<h3>Recommended doses of statins in adults with CKD<\/h3>\n\n<table class=\"statin_dosages\">\n\t<tr>\n\t\t<th>Statin<\/th>\n\t\t<th><div class=\"tooltip2\">eGFR<span>estimated glomerular filtration rate<\/span><\/div> G1 - G2 (<a href=\"img\/Prognosis of CKD by GFR and albuminuria category.png\" target=\"_blank\" style=\"font-weight: normal\">details<\/a>)<\/th>\n\t\t<th>\n\t\t\t<div class=\"tooltip2\">eGFR<span>estimated glomerular filtration rate<\/span><\/div> G3a - G5\n\t\t\t<div class=\"tooltip2\">**<span>incl. dialysis or kidney transplant patients<\/span><\/div>\n\t\t\t(<a href=\"img\/Prognosis of CKD by GFR and albuminuria category.png\" target=\"_blank\" style=\"font-weight: normal\">details<\/a>)\n\t\t<\/th>\n\t<\/tr>\n\t<tr>\n\t\t<td><\/td>\n\t\t<td><span style=\"font-size: 14px;\">(60 to >=90 ml\/min\/1.73m&sup2)<\/span><\/td>\n\t\t<td><span style=\"font-size: 14px;\">(up to 59 ml\/min\/1.73m&sup2)<\/span><\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Lovastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td><div class=\"tooltip2\">nd<span>not done or not studied<\/span><\/div><\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Fluvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>80<div class=\"tooltip2\"><sup>1<\/sup><span>Data based on ALERT.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Atorvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>20<div class=\"tooltip2\"><sup>2<\/sup><span>Data based on 4D.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Rosuvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>10<div class=\"tooltip2\"><sup>3<\/sup><span>Data based on AURORA.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Simvastatin\/Ezetmibe<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>20 \/ 10<div class=\"tooltip2\"><sup>4<\/sup><span>Data based on SHARP.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Pravastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>40 mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Simvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>40 mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Pitavastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>2 mg\/d<\/td>\n\t<\/tr>\n<\/table>\n\n<p class=\"dosage_note\">** incl. dialysis or kidney transplant patients.<\/p>\n<p class=\"dosage_note\">All statins may not be available in all countries. Lower doses than those used in major trials of statins in CKD populations may be appropriate in Asian countries. Note that rosuvastatin 40mg daily is not recommended for use in CKD 1-2 non- transplant patients, as it may increase the risk of adverse renal events. Cyclosporin inhibits the metabolism of certain statins resulting in higher blood levels. Data based on <sup>1<\/sup>ALERT, <sup>2<\/sup>4D, <sup>3<\/sup>AURORA, <sup>4<\/sup>SHARP. Abbreviations: eGFR, estimated glomerular filtration rate; GP, general population; nd, not done or not studied.<\/p>\n"},{"id": "assess_kidney_transplant-1","name": "Kidney transplant?","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-1","otherParents": [{"id": "assess_age_start-1","condition": {"label": "18-49 years"}}],"node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "< 60","description": "< 60 ml\/min\/ 1.73m2"},"inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_kidney_transplant'><\/span><div id='code_kidney_transplant' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean'>Kidney transplant?: <label><input type='radio' name='code_kidney_transplant' id='code_kidney_transplant-yes' code='code_kidney_transplant-yes' value='yes' \/>yes<\/label>&nbsp;&nbsp;<label><input type='radio' name='code_kidney_transplant' id='code_kidney_transplant-no' code='code_kidney_transplant-no' value='no' \/>no<\/label><\/div><\/td><\/tr><\/table>\n","children": [{"id": "treat_statin_kidney_transplant-1","name": "treat with statins","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-1","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "yes"},"description": "2.4: In adult kidney transplant recipients, we suggest treatment with a statin. (2B)","insert": "<b>Contra-indications for statins:<\/b>\n<ul style=\"margin: 0; padding: 0 0 0 15px;\">\n\t<li>Active liver disease, high alcohol consumption or pregnancy.<\/li>\n    <li>Women with childbearing potential should only use statin if there is reliable contraception.<\/li>\n<\/ul>\n\n<h3>Recommended doses of statins in adults with CKD<\/h3>\n\n<table class=\"statin_dosages\">\n\t<tr>\n\t\t<th>Statin<\/th>\n\t\t<th><div class=\"tooltip2\">eGFR<span>estimated glomerular filtration rate<\/span><\/div> G1 - G2 (<a href=\"img\/Prognosis of CKD by GFR and albuminuria category.png\" target=\"_blank\" style=\"font-weight: normal\">details<\/a>)<\/th>\n\t\t<th>\n\t\t\t<div class=\"tooltip2\">eGFR<span>estimated glomerular filtration rate<\/span><\/div> G3a - G5\n\t\t\t<div class=\"tooltip2\">**<span>incl. dialysis or kidney transplant patients<\/span><\/div>\n\t\t\t(<a href=\"img\/Prognosis of CKD by GFR and albuminuria category.png\" target=\"_blank\" style=\"font-weight: normal\">details<\/a>)\n\t\t<\/th>\n\t<\/tr>\n\t<tr>\n\t\t<td><\/td>\n\t\t<td><span style=\"font-size: 14px;\">(60 to >=90 ml\/min\/1.73m&sup2)<\/span><\/td>\n\t\t<td><span style=\"font-size: 14px;\">(up to 59 ml\/min\/1.73m&sup2)<\/span><\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Lovastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td><div class=\"tooltip2\">nd<span>not done or not studied<\/span><\/div><\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Fluvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>80<div class=\"tooltip2\"><sup>1<\/sup><span>Data based on ALERT.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Atorvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>20<div class=\"tooltip2\"><sup>2<\/sup><span>Data based on 4D.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Rosuvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>10<div class=\"tooltip2\"><sup>3<\/sup><span>Data based on AURORA.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Simvastatin\/Ezetmibe<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>20 \/ 10<div class=\"tooltip2\"><sup>4<\/sup><span>Data based on SHARP.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Pravastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>40 mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Simvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>40 mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Pitavastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>2 mg\/d<\/td>\n\t<\/tr>\n<\/table>\n\n<p class=\"dosage_note\">** incl. dialysis or kidney transplant patients.<\/p>\n<p class=\"dosage_note\">All statins may not be available in all countries. Lower doses than those used in major trials of statins in CKD populations may be appropriate in Asian countries. Note that rosuvastatin 40mg daily is not recommended for use in CKD 1-2 non- transplant patients, as it may increase the risk of adverse renal events. Cyclosporin inhibits the metabolism of certain statins resulting in higher blood levels. Data based on <sup>1<\/sup>ALERT, <sup>2<\/sup>4D, <sup>3<\/sup>AURORA, <sup>4<\/sup>SHARP. Abbreviations: eGFR, estimated glomerular filtration rate; GP, general population; nd, not done or not studied.<\/p>\n"},{"id": "assess_dialysis_treatment-1","name": "Treatment with dialysis?","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-1","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "no"},"inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_dialysis_treatment'><\/span><div id='code_dialysis_treatment' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean'>Treatment with dialysis?: <label><input type='radio' name='code_dialysis_treatment' id='code_dialysis_treatment-yes' code='code_dialysis_treatment-yes' value='yes' \/>yes<\/label>&nbsp;&nbsp;<label><input type='radio' name='code_dialysis_treatment' id='code_dialysis_treatment-no' code='code_dialysis_treatment-no' value='no' \/>no<\/label><\/div><\/td><\/tr><\/table>\n","children": [{"id": "assess_statin_use-1","name": "Using statins or statin/ezetimibe?","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-1","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "yes"},"inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_statin_ezetimibe'><\/span><div id='code_statin_ezetimibe' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean'>Using statins or statin\/ezetimibe?: <label><input type='radio' name='code_statin_ezetimibe' id='code_statin_ezetimibe-yes' code='code_statin_ezetimibe-yes' value='yes' \/>yes<\/label>&nbsp;&nbsp;<label><input type='radio' name='code_statin_ezetimibe' id='code_statin_ezetimibe-no' code='code_statin_ezetimibe-no' value='no' \/>no<\/label><\/div><\/td><\/tr><\/table>\n","children": [{"id": "continue_statin_treatment-1","name": "continue statin or statin/ezetimibe","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-1","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "yes"},"description": "2.3.2: In patients already receiving statins or statin\/ezetimibe combination at the time of dialysis initiation, we suggest that these agents be continued. (2C)","insert": "<b>Contra-indications for statins:<\/b>\n<ul style=\"margin: 0; padding: 0 0 0 15px;\">\n\t<li>Active liver disease, high alcohol consumption or pregnancy.<\/li>\n    <li>Women with childbearing potential should only use statin if there is reliable contraception.<\/li>\n<\/ul>\n\n<h3>Recommended doses of statins in adults with CKD<\/h3>\n\n<table class=\"statin_dosages\">\n\t<tr>\n\t\t<th>Statin<\/th>\n\t\t<th><div class=\"tooltip2\">eGFR<span>estimated glomerular filtration rate<\/span><\/div> G1 - G2 (<a href=\"img\/Prognosis of CKD by GFR and albuminuria category.png\" target=\"_blank\" style=\"font-weight: normal\">details<\/a>)<\/th>\n\t\t<th>\n\t\t\t<div class=\"tooltip2\">eGFR<span>estimated glomerular filtration rate<\/span><\/div> G3a - G5\n\t\t\t<div class=\"tooltip2\">**<span>incl. dialysis or kidney transplant patients<\/span><\/div>\n\t\t\t(<a href=\"img\/Prognosis of CKD by GFR and albuminuria category.png\" target=\"_blank\" style=\"font-weight: normal\">details<\/a>)\n\t\t<\/th>\n\t<\/tr>\n\t<tr>\n\t\t<td><\/td>\n\t\t<td><span style=\"font-size: 14px;\">(60 to >=90 ml\/min\/1.73m&sup2)<\/span><\/td>\n\t\t<td><span style=\"font-size: 14px;\">(up to 59 ml\/min\/1.73m&sup2)<\/span><\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Lovastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td><div class=\"tooltip2\">nd<span>not done or not studied<\/span><\/div><\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Fluvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>80<div class=\"tooltip2\"><sup>1<\/sup><span>Data based on ALERT.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Atorvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>20<div class=\"tooltip2\"><sup>2<\/sup><span>Data based on 4D.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Rosuvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>10<div class=\"tooltip2\"><sup>3<\/sup><span>Data based on AURORA.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Simvastatin\/Ezetmibe<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>20 \/ 10<div class=\"tooltip2\"><sup>4<\/sup><span>Data based on SHARP.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Pravastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>40 mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Simvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>40 mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Pitavastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>2 mg\/d<\/td>\n\t<\/tr>\n<\/table>\n\n<p class=\"dosage_note\">** incl. dialysis or kidney transplant patients.<\/p>\n<p class=\"dosage_note\">All statins may not be available in all countries. Lower doses than those used in major trials of statins in CKD populations may be appropriate in Asian countries. Note that rosuvastatin 40mg daily is not recommended for use in CKD 1-2 non- transplant patients, as it may increase the risk of adverse renal events. Cyclosporin inhibits the metabolism of certain statins resulting in higher blood levels. Data based on <sup>1<\/sup>ALERT, <sup>2<\/sup>4D, <sup>3<\/sup>AURORA, <sup>4<\/sup>SHARP. Abbreviations: eGFR, estimated glomerular filtration rate; GP, general population; nd, not done or not studied.<\/p>\n"},{"id": "do_not_initiate_statins-1","name": "do not initiate statins","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-1","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "no"},"description": "2.3.1: In adults with dialysis-dependent CKD, we suggest that statins or statin\/ezetimibe combination not be initiated. (2A)"}]},{"id": "assess_age_no_dialysis-1","name": "Age?","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-1","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "no"},"inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_age'><\/span><div property='http:\/\/hl7.org\/fhir\/Observation.valueQuantity' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.system' resource='http:\/\/unitsofmeasure.org'><\/span><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.code'>year<\/span>Age? <input type='number' id='code_age' code='code_age' min='1' max='120' step='1' size='2' property='http:\/\/hl7.org\/fhir\/Quantity.value' \/> (1-120)<\/div><\/td><\/tr><\/table>\n","children": [{"id": "assess_cv_risk-1","name": "assess CV risk","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-1","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "18-49 years"},"description": "Note that CV risk should be re-assessed on an annual basis, as changes in clinical condition may warrant treatment with a statin.","inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_no_cv_risk_factors'><\/span><label><input type='checkbox' id='code_no_cv_risk_factors' code='code_no_cv_risk_factors' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_prior_mi,code_prior_coronary_revascularization,code_prior_ischemic_stroke,code_prior_transient_ischemic_attack,code_diabetes,code_estimated_10-year_incidence_coronary_death,code_likelihood_non_fatal_mi' mandatory='false' \/>No CV risk factors<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_prior_mi'><\/span><label><input type='checkbox' id='code_prior_mi' code='code_prior_mi' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_cv_risk_factors' mandatory='false' \/>Prior MI?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_prior_coronary_revascularization'><\/span><label><input type='checkbox' id='code_prior_coronary_revascularization' code='code_prior_coronary_revascularization' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_cv_risk_factors' mandatory='false' \/>Prior Coronary Revascularization?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_prior_ischemic_stroke'><\/span><label><input type='checkbox' id='code_prior_ischemic_stroke' code='code_prior_ischemic_stroke' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_cv_risk_factors' mandatory='false' \/>Prior ischemic stroke?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_prior_transient_ischemic_attack'><\/span><label><input type='checkbox' id='code_prior_transient_ischemic_attack' code='code_prior_transient_ischemic_attack' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_cv_risk_factors' mandatory='false' \/>Prior transient ischemic attack?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_diabetes'><\/span><label><input type='checkbox' id='code_diabetes' code='code_diabetes' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_cv_risk_factors' mandatory='false' \/>Diabetes?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_estimated_10-year_incidence_coronary_death'><\/span><label><input type='checkbox' id='code_estimated_10-year_incidence_coronary_death' code='code_estimated_10-year_incidence_coronary_death' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean' mutex-with='code_no_cv_risk_factors' mandatory='false' \/>Estimated 10-year incidence of coronary death?<\/label><\/td><\/tr><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_likelihood_non_fatal_mi'><\/span><div property='http:\/\/hl7.org\/fhir\/Observation.valueQuantity' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.system' resource='http:\/\/unitsofmeasure.org'><\/span><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.code'>%<\/span>Likelihood of non-fatal MI (<a href=\"https:\/\/www.mdcalc.com\/framingham-risk-score-hard-coronary-heart-disease\" target=\"_blank\">calculate<\/a>) <input type='number' id='code_likelihood_non_fatal_mi' code='code_likelihood_non_fatal_mi' min='1' max='100' step='1' size='2' property='http:\/\/hl7.org\/fhir\/Quantity.value' \/> (1-100)<\/div><\/td><\/tr><\/table>\n","children": [{"id": "treat_statin_high_risk-1","name": "treat with statin","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-1","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "high risk","description": "Prior MI or\nPrior Coronary revascularization or\nPrior ischemic stroke or Transient ischemic attack or\nDiabetes or\nEstimated 10-year incidence of coronary death or non-fatal MI >10% using a validated risk calculator"},"description": "2.2: In adults aged 18\u201349 years with CKD but not treated with chronic dialysis or kidney transplantation, we\nsuggest statin treatment in people with one or more of the following (2A):\n\u2022\tknown coronary disease (myocardial infarction or coronary revascularization)\n\u2022\tdiabetes mellitus\n\u2022\tprior ischemic stroke\n\u2022\testimated 10-year incidence of coronary death or non-fatal myocardial infarction >10%","insert": "<b>Contra-indications for statins:<\/b>\n<ul style=\"margin: 0; padding: 0 0 0 15px;\">\n\t<li>Active liver disease, high alcohol consumption or pregnancy.<\/li>\n    <li>Women with childbearing potential should only use statin if there is reliable contraception.<\/li>\n<\/ul>\n\n<h3>Recommended doses of statins in adults with CKD<\/h3>\n\n<table class=\"statin_dosages\">\n\t<tr>\n\t\t<th>Statin<\/th>\n\t\t<th><div class=\"tooltip2\">eGFR<span>estimated glomerular filtration rate<\/span><\/div> G1 - G2 (<a href=\"img\/Prognosis of CKD by GFR and albuminuria category.png\" target=\"_blank\" style=\"font-weight: normal\">details<\/a>)<\/th>\n\t\t<th>\n\t\t\t<div class=\"tooltip2\">eGFR<span>estimated glomerular filtration rate<\/span><\/div> G3a - G5\n\t\t\t<div class=\"tooltip2\">**<span>incl. dialysis or kidney transplant patients<\/span><\/div>\n\t\t\t(<a href=\"img\/Prognosis of CKD by GFR and albuminuria category.png\" target=\"_blank\" style=\"font-weight: normal\">details<\/a>)\n\t\t<\/th>\n\t<\/tr>\n\t<tr>\n\t\t<td><\/td>\n\t\t<td><span style=\"font-size: 14px;\">(60 to >=90 ml\/min\/1.73m&sup2)<\/span><\/td>\n\t\t<td><span style=\"font-size: 14px;\">(up to 59 ml\/min\/1.73m&sup2)<\/span><\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Lovastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td><div class=\"tooltip2\">nd<span>not done or not studied<\/span><\/div><\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Fluvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>80<div class=\"tooltip2\"><sup>1<\/sup><span>Data based on ALERT.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Atorvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>20<div class=\"tooltip2\"><sup>2<\/sup><span>Data based on 4D.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Rosuvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>10<div class=\"tooltip2\"><sup>3<\/sup><span>Data based on AURORA.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Simvastatin\/Ezetmibe<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>20 \/ 10<div class=\"tooltip2\"><sup>4<\/sup><span>Data based on SHARP.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Pravastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>40 mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Simvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>40 mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Pitavastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>2 mg\/d<\/td>\n\t<\/tr>\n<\/table>\n\n<p class=\"dosage_note\">** incl. dialysis or kidney transplant patients.<\/p>\n<p class=\"dosage_note\">All statins may not be available in all countries. Lower doses than those used in major trials of statins in CKD populations may be appropriate in Asian countries. Note that rosuvastatin 40mg daily is not recommended for use in CKD 1-2 non- transplant patients, as it may increase the risk of adverse renal events. Cyclosporin inhibits the metabolism of certain statins resulting in higher blood levels. Data based on <sup>1<\/sup>ALERT, <sup>2<\/sup>4D, <sup>3<\/sup>AURORA, <sup>4<\/sup>SHARP. Abbreviations: eGFR, estimated glomerular filtration rate; GP, general population; nd, not done or not studied.<\/p>\n"},{"id": "no_statin_treatment_low_risk-1","name": "do not initiate statins","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-1","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "no","description": "No CV risk factor or \nEstimated 10-year incidence of coronary death or non-fatal MI >10% using a validated risk calculator"}}]},{"id": "treat_statin_no_dialysis-1","name": "treat with statins or statin/ezetimibe","composed": false,"in_workflow": "Pharmacological_Cholesterol_Lowering_Treatment-1","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": ">= 50 years"},"insert": "<b>Contra-indications for statins:<\/b>\n<ul style=\"margin: 0; padding: 0 0 0 15px;\">\n\t<li>Active liver disease, high alcohol consumption or pregnancy.<\/li>\n    <li>Women with childbearing potential should only use statin if there is reliable contraception.<\/li>\n<\/ul>\n\n<h3>Recommended doses of statins in adults with CKD<\/h3>\n\n<table class=\"statin_dosages\">\n\t<tr>\n\t\t<th>Statin<\/th>\n\t\t<th><div class=\"tooltip2\">eGFR<span>estimated glomerular filtration rate<\/span><\/div> G1 - G2 (<a href=\"img\/Prognosis of CKD by GFR and albuminuria category.png\" target=\"_blank\" style=\"font-weight: normal\">details<\/a>)<\/th>\n\t\t<th>\n\t\t\t<div class=\"tooltip2\">eGFR<span>estimated glomerular filtration rate<\/span><\/div> G3a - G5\n\t\t\t<div class=\"tooltip2\">**<span>incl. dialysis or kidney transplant patients<\/span><\/div>\n\t\t\t(<a href=\"img\/Prognosis of CKD by GFR and albuminuria category.png\" target=\"_blank\" style=\"font-weight: normal\">details<\/a>)\n\t\t<\/th>\n\t<\/tr>\n\t<tr>\n\t\t<td><\/td>\n\t\t<td><span style=\"font-size: 14px;\">(60 to >=90 ml\/min\/1.73m&sup2)<\/span><\/td>\n\t\t<td><span style=\"font-size: 14px;\">(up to 59 ml\/min\/1.73m&sup2)<\/span><\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Lovastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td><div class=\"tooltip2\">nd<span>not done or not studied<\/span><\/div><\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Fluvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>80<div class=\"tooltip2\"><sup>1<\/sup><span>Data based on ALERT.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Atorvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>20<div class=\"tooltip2\"><sup>2<\/sup><span>Data based on 4D.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Rosuvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>10<div class=\"tooltip2\"><sup>3<\/sup><span>Data based on AURORA.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Simvastatin\/Ezetmibe<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>20 \/ 10<div class=\"tooltip2\"><sup>4<\/sup><span>Data based on SHARP.<\/span><\/div> mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Pravastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>40 mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Simvastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>40 mg\/d<\/td>\n\t<\/tr>\n\t<tr>\n\t\t<td>Pitavastatin<\/td>\n\t\t<td><div class=\"tooltip2\">GP<span>general population<\/span><\/div><\/td>\n\t\t<td>2 mg\/d<\/td>\n\t<\/tr>\n<\/table>\n\n<p class=\"dosage_note\">** incl. dialysis or kidney transplant patients.<\/p>\n<p class=\"dosage_note\">All statins may not be available in all countries. Lower doses than those used in major trials of statins in CKD populations may be appropriate in Asian countries. Note that rosuvastatin 40mg daily is not recommended for use in CKD 1-2 non- transplant patients, as it may increase the risk of adverse renal events. Cyclosporin inhibits the metabolism of certain statins resulting in higher blood levels. Data based on <sup>1<\/sup>ALERT, <sup>2<\/sup>4D, <sup>3<\/sup>AURORA, <sup>4<\/sup>SHARP. Abbreviations: eGFR, estimated glomerular filtration rate; GP, general population; nd, not done or not studied.<\/p>\n"}]}]}]}]},{"hidden": true}]},{"id": "statin_prescribed-1","name": "Statins prescribed?","composed": false,"in_workflow": "Dyslipidemia_Treatment-1","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","description": "Were any statins prescribed for cholesterol lowering treatment?","inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_statin_prescribed'><\/span><div id='code_statin_prescribed' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean'>Any statins prescribed for cholesterol lowering treatment?: <label><input type='radio' name='code_statin_prescribed' id='code_statin_prescribed-yes' code='code_statin_prescribed-yes' value='yes' \/>yes<\/label>&nbsp;&nbsp;<label><input type='radio' name='code_statin_prescribed' id='code_statin_prescribed-no' code='code_statin_prescribed-no' value='no' \/>no<\/label><\/div><\/td><\/tr><\/table>\n","children": [{"id": "no_statin_no_followup-1","name": "No followup","composed": false,"in_workflow": "Dyslipidemia_Treatment-1","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "no"}},{"id": "fasting_serum_tgs_values-1","name": "Check Fasting Serum TGs Values","composed": false,"in_workflow": "Dyslipidemia_Treatment-1","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "yes"},"inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_fasting_serum_tg'><\/span><div property='http:\/\/hl7.org\/fhir\/Observation.valueQuantity' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.system' resource='http:\/\/unitsofmeasure.org'><\/span><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.code'>mmol\/L<\/span>Fasting serum TGs value <input type='number' id='code_fasting_serum_tg' code='code_fasting_serum_tg' min='1' max='100' step='0.01' size='2' property='http:\/\/hl7.org\/fhir\/Quantity.value' \/> (1-100)<\/div><\/td><\/tr><\/table>\n","children": [{"id": "low_fasting_serum_no_followup-1","name": "No followup","composed": false,"in_workflow": "Dyslipidemia_Treatment-1","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "<=5.65mmol/l","description": "<=5.65mmol\/l (>500mg\/dl)"}},{"id": "assess_malnutrition-1","name": "Malnutrition?","composed": false,"in_workflow": "Dyslipidemia_Treatment-1","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": ">5.65mmol/l","description": ">5.65mmol\/l (>500mg\/dl)"},"inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_malnutrition'><\/span><div id='code_malnutrition' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean'>Malnutrition?: <label><input type='radio' name='code_malnutrition' id='code_malnutrition-yes' code='code_malnutrition-yes' value='yes' \/>yes<\/label>&nbsp;&nbsp;<label><input type='radio' name='code_malnutrition' id='code_malnutrition-no' code='code_malnutrition-no' value='no' \/>no<\/label><\/div><\/td><\/tr><\/table>\n","children": [{"id": "prescribe_lifestyle_changes_judiciously-1","name": "Judicious lifestyle changes","composed": false,"in_workflow": "Dyslipidemia_Treatment-1","node_type": "atomic_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "yes","description": "Malnutrition found."},"description": "Prescribe Therapeutic Lifestyle Changes judiciously with caution.","children": [{"hidden": true},{"id": "fasting_serum_tgs_values2-1","name": "Check Fasting Serum TGs Values (2)","composed": false,"in_workflow": "Dyslipidemia_Treatment-1","otherParents": [{"id": "prescribe_lifestyle_changes-1","condition": null}],"node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_fasting_serum_tg'><\/span><div property='http:\/\/hl7.org\/fhir\/Observation.valueQuantity' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.system' resource='http:\/\/unitsofmeasure.org'><\/span><span style='display: none' property='http:\/\/hl7.org\/fhir\/Quantity.code'>mmol\/L<\/span>Fasting serum TGs value <input type='number' id='code_fasting_serum_tg' code='code_fasting_serum_tg' min='1' max='100' step='0.01' size='2' property='http:\/\/hl7.org\/fhir\/Quantity.value' \/> (1-100)<\/div><\/td><\/tr><\/table>\n","children": [{"id": "low_fasting_serum_no_followup2-1","name": "No followup","composed": false,"in_workflow": "Dyslipidemia_Treatment-1","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "<=11.3mmol/l","description": "<=11.3mmol\/l (<=1000mg\/dl)"}},{"id": "avoid_nicotinic_acid-1","name": "Avoid nicotinic acid","composed": false,"in_workflow": "Dyslipidemia_Treatment-1","node_type": "atomic_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": ">11.3mmol/l","description": ">11.3mmol\/l (<=1000mg\/dl)"},"description": "Nicotinic Acid has not been well studied in advanced CKD and therefore is not recommended for the treatment of severe hypertriglyceridemia.","children": [{"id": "assess_prevent_pancreatitis-1","name": "Prevent pancreatitis?","composed": false,"in_workflow": "Dyslipidemia_Treatment-1","node_type": "decision_task","workflow_state": "inactiveState","decisional_state": "chosenState","description": "Have a conversation with patient regarding pros and cons of treatment with statin vs. fibric acid derivatives and their preference, especially regarding prevention of pancreatitis. (Concomitant therapy with fibric acid derivative and a statin is not recommended in patient with CKD due to the potential for toxicity.)","inputForm": "<table><tr><td property='http:\/\/hl7.org\/fhir\/DiagnosticReport.result' typeof=''><span style='display: none' property='http:\/\/hl7.org\/fhir\/Observation.code' resource='http:\/\/niche.cs.dal.ca\/ns\/cig\/kidney_statins.owl#code_prevent_pancreatitis'><\/span><div id='code_prevent_pancreatitis' property='http:\/\/hl7.org\/fhir\/Observation.valueBoolean'>Does the patient place high value on preventing pancreatitis?: <label><input type='radio' name='code_prevent_pancreatitis' id='code_prevent_pancreatitis-yes' code='code_prevent_pancreatitis-yes' value='yes' \/>yes<\/label>&nbsp;&nbsp;<label><input type='radio' name='code_prevent_pancreatitis' id='code_prevent_pancreatitis-no' code='code_prevent_pancreatitis-no' value='no' \/>no<\/label><\/div><\/td><\/tr><\/table>\n","children": [{"id": "prescribe_fibric_acid_pancreatitis-1","name": "Prescribe fibric acid","composed": false,"in_workflow": "Dyslipidemia_Treatment-1","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "yes","description": "Patient places high value on preventing pancreatitis."},"description": "Fibric acid derivatives could be considered. \n\tIf considered, fibric acid should be dose adjusted for kidney function. \n\tFibric acid derivatives might be warranted in patients who place a relatively high value in preventing pancreatitis and a relatively low value on the risk of CV disease."},{"id": "do_not_prescribe_fibric_acid_pancreatitis-1","name": "No fibric acid","composed": false,"in_workflow": "Dyslipidemia_Treatment-1","node_type": "endpoint","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "no","description": "Patient does not place high value on preventing pancreatitis."},"description": "Fibric acid derivatives should not be considered."}]}]}]}]},{"id": "prescribe_lifestyle_changes-1","name": "Lifestyle changes","composed": false,"in_workflow": "Dyslipidemia_Treatment-1","node_type": "atomic_task","workflow_state": "inactiveState","decisional_state": "chosenState","condition": {"label": "no","description": "No malnutrition found."},"description": "Prescribe Therapeutic Lifestyle Changes:\n\u2022\tLow Fat diet (<15% total calories)\n\u2022\tReduce monosaccharides & disaccharides intake\n\u2022\tReduce total amount of dietary carbohydrates\n\u2022\tUse fish oils to replace some long-chain TGs","children": []}]}]}]}]}]}]}]}]}